Physicians' Academy for Cardiovascular Education

GLP-1RA induces weight loss in adults with overweight or obesity

10' education - Mar. 2, 2021 - Prof. Robert Kushner, MD

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

Rise in ANP might mediate benefits of ARNI in HFrEF

10' education - Feb. 16, 2021 - Sean Murphy, MD

Anti-inflammation heralds the future of CV medicine

10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD

No decrease in thrombotic complications in second COVID-19 wave

5' education - Feb. 4, 2021 - Fleur Kaptein, MD

Two medical therapies elevated to front line in 2021 update HF ECDP

5' education - Feb. 1, 2021 - Prof. James Januzzi, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Older adults should also be treated to lower LDL-c

5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD

Explained risk from apoB-containing lipoproteins to MI

5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
5 Things a cardiologist needs to know about GLP-1 RA

GLP-1RAs: What are the future directions in development?

10' education - Jan. 6, 2021 - Prof. John Deanfield, MD

Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF

3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
5 Things a cardiologist needs to know about GLP-1 RA

What is the clinical evidence for the benefits of GLP-1RAs?

10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD
5 Things a cardiologist needs to know about GLP-1RA

Role of GLP-1RA in practice

10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD
5 Things a cardiologist needs to know about GLP-1RA

How do GLP-1RAs work?

10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD

Newest ESC guidelines on diabetes and CVD

10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD

Update on COVID-19 at AHA Scientific Sessions

10' education - Nov. 24, 2020 - Anthony Fauci, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations

5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD

Strengths and limitations of one-month DAPT trial

3' education - Nov. 19, 2020 - Róisín Colleran, MD

NT-proBNP outperforms ESC/EASD risk model for 10-year fatal CVD risk prediction in T2DM cohort

Literature - Mar. 5, 2021 - Prausmüller S, et al. - Cardiovasc Diabetol. 2021

The ESC/EASD risk model was less accurate in prediction of 10-year CVD and all-cause mortality in patients with T2DM compared to SCORE and most notably to single assessment of NT-proBNP.

CVD risk associated with lower SBP range in women than in men

Literature - Mar. 5, 2021 - Ji H et al. - Circulation. 2021.

This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.

Lower rate of cholesterol testing during COVID-19 pandemic

Literature - Mar. 3, 2021 - Gumuser ED, et al. - Am J Prev Cardiol 2021
Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

Compared to the same period in 2019, cholesterol testing rate was almost 40% lower between March-September 2020 when analyzing data from a healthcare system in New England, USA.

Causal relationship between blood pressure and AF risk

Literature - Mar. 2, 2021 - Georgiopoulos G, et al. - Eur J Prev Cardiol. 2021

This Mendelian randomization study provided first evidence that the relationship between BP and risk for new-onset AF is likely causal.

GLP-1RA induces weight loss in adults with overweight or obesity

10' education - Mar. 2, 2021 - Prof. Robert Kushner, MD
Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.

Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.

Enhanced safety advantage with DOAC in women with AF

Literature - Mar. 1, 2021 - Zelniker TA et al. - Circulation. 2021

Effect of edoxaban versus warfarin on the primary efficacy endpoint and primary safety endpoint was similar in women and men. However, edoxaban reduced risk of several bleeding outcomes to a greater extend in women compared to men.

Association between green tea and coffee consumption and all-cause mortality

Literature - Mar. 1, 2021 - Teramoto M, et al. - Stroke. 2021
Higher consumption of green tea was associated with lower all-cause mortality in persons with a history of stroke and MI, whereas higher coffee consumption was associated with lower risk in those without history of CVD and in those with MI.

Higher consumption of green tea was associated with lower all-cause mortality in persons with a history of stroke and MI, whereas higher coffee consumption was associated with lower risk in those without history of CVD and in those with MI.

Efficacy of two SGLT2i on CV and kidney outcomes in HFrEF according to kidney function

Literature - Feb. 25, 2021 - Jhund PS et al. and Zannad F et al., - Circulation. 2021

Subgroup analyses from DAPA-HF and EMPEROR-Reduced evaluated the effects of dapagliflozin and empagliflozin on CV and kidney outcomes according to baseline kidney function in patients with HFrEF.

ACC statement on CV considerations for COVID-19 vaccine allocation

News - Feb. 23, 2021

The ACC has published a statement with key clinical risk considerations that offers guidance on the incorporation of CV risk into vaccine allocation prioritizing decisions.

Two phase 3 trials with dual GIP/GLP-1RA in T2DM meet primary and key secondary endpoints

News - Feb. 23, 2021

Tirzepatide, a dual glucose-dependent insulinotropic peptide/GLP-1 receptor agonist (GIP/GLP-1RA), significantly improved glycemic control and reduced body weight in patients with T2DM.

Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM

10' education - Feb. 22, 2021 - Frederik Persson, MD
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD
What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

What is the mechanism of action resulting in benefit with SGLT2i? Carlos Santos-Gallego discusses the results of the EMPA-TROPISM trial that shows reverse LV remodeling by empagliflozin in non-diabetic HFrEF.

Agenda